T
HE chelated paramagnetic compound gadolinium-diethylenetriaminepenta-acetic acid (Gd-DTPA) is available as a contrast agent for use in magnetic resonance (MR) imaging. This agent defines areas of loss of blood-brain barrier integrity by causing increased signal intensity on T~-weighted images. To assess the utility of Gd-DTPA-enhanced MR imaging in delineating tumor recurrence, a group of pediatric patients were evaluated following brain-tumor resection.
Clinical Material and Methods
An experimental protocol was established in which MR imaging studies were performed using a General Electric 1.5-tesla Signa Unit.* Informed consent as approved by the Institutional Review Board of St. * Signa Unit manufactured by General Electric, Milwaukee, Wisconsin.
Joseph's Hospital and Medical Center was obtained. Precontrast TI-, intermediate-, and T2-weighted imaging was performed. Gadolinium-DTPA was then injected intravenously at a dose of 0.1 mmol/kg body weight as part of a multicenter pediatric protocol.t Spin-echo Tl-weighted images (TR 600 msec, TE 20 msec) were obtained within 5 minutes, spin-echo T2-weighted images (TR 2500 msec, TE 40, and 80 msec) within 15 minutes, and a second series of T~-weighted images within 20 minutes following injection of contrast material. Laboratory studies (including electrolyte studies, complete blood count, urinalysis, renal and liver function, and serum iron determination) as well as physical examinations were performed prior to MR imaging and at regular intervals thereafter.
The patients' radiographic studies and case histories t Gd-DPTA obtained from Berlex Laboratories, Cedar Knolls, New Jersey. tionally, t h e p r e c o n t r a s t a n d p o s t c o n t r a s t studies were c o m p a r e d q u a l i t a t i v e l y a n d q u a n t i t a t i v e l y to d e t e r m i n e t h e p r e s e n c e o f residual t u m o r or t u m o r r e c u r r e n c e . 
Results

F i f t e e n p e d i a t r i c p a t i e n t s received i n j e c t i o n s o f G d -D T P A in t h e p o s t o p e r a t i v e e v a l u a t i o n o f t h e i r b r a i n n e o p l a s m s . T h e p a t i e n t s c h a r a c t e r i s t i c s are d i s p l a y e d in
T a b l e 1. T h e r e were 11 b o y s ( m e a n age 9.2 years, r a n g e 2 to 14 years) a n d f o u r girls ( m e a n age 9.8 years, r a n g e 2 to 14 years). T h e m e d i a n i n t e r v a l f r o m t h e m o s t r e c e n t n e u r o s u r g i c a l p r o c e d u r e for t r e a t m e n t o f t u m o r identification of tumor not suspected on 2 unenhanced scans (isomagnetic lesion) tumor vs. edema distinction possible without 2 contrast enhancement improved delineation of tumor boundaries 9 with Gd-DTPA studies improved differentiation of tumor core with 7 Gd-DTPA studies abnormal unenhanced studies (T2) suspicious 13 for residual or recurrent tumor * MR = magnetic resonance; Gd-DTPA = gadolinium-diethylenetriaminepenta-acetic acid. Gd-DTPA-enhanced M R imaging in pediatric brain tumors to the enhanced MR study was 6 months (range 4 days to 2 years). Follow-up evaluation was obtained in all patients at a median interval of 8 months. None of the patients experienced any allergic or other adverse reactions following the administration of Gd-DTPA.
The tumor types were diverse. Five patients had astrocytomas, two had medulloblastomas, and two had craniopharyngiomas; one patient had each of the following tumors: pineocytoma, pineal teratoma, leptomeningeal melanoma, choroid plexus carcinoma, ependymoma, and primitive neuroectodermal tumor. Thirteen patients underwent craniotomy with gross total tumor resection prior to their enhanced MR studies. Two patients had a tumor biopsy performed. The initial postoperative treatment and MR imaging results are detailed in Table 1 .
In 14 of the 15 patients, the unenhanced T~-weighted images were without evidence of tumor. In all 15 patients, the enhanced T2-weighted images were not useful because of their display of increased tissue water content, which masked the appearance of contrast-enhancing regions. The unenhanced T2-and enhanced T~-weighted images provided useful information and are therefore the focus of our analysis.
Residual or recurrent tumors were identified in nine of the 15 patients on the basis of the Gd-DTPAenhanced MR studies. Tables 1 and 2 outline the MR imaging findings. In 13 patients (87%), the unenhanced T2-weighted studies were abnormal, which raised the suspicion of residual or recurrent tumor. This issue was resolved in all cases after the administration of contrast material. Seven of these patients had enhancing lesions, indicating the presence of tumor. Of these seven patients, four underwent surgery with histological confirmation of residual tumor. Therefore, contrast enhancement appears to be useful in distinguishing the presence or absence of tumor in cases with suspicious unenhanced T2-weighted studies.
When tumor was present, the contrast-enhanced studies demonstrated the location and extent of neoplastic tissue more clearly than the unenhanced studies ( Figs. 1 and 2 ). Six patients with abnormal TR-weighted unenhanced studies had no evidence of residual neoplasm after the administration of Gd-DTPA. Tumors not suspected on unenhanced studies were identified in two patients after the administration of contrast medium. In all cases with residual or recurrent tumor, the administration of contrast material improved delineation of the tumor boundaries. Contrast-enhanced imaging also improved differentiation of the tumor core.
Gadolinium-DTPA-enhanced MR images played an important role in determining the treatment and surveillance regimens of the patients in our study. The Gd-DTPA-enhanced studies confirmed the suspicion of residual tumor in seven patients and excluded it in six patients with abnormal unenhanced studies. Gadolinium-DTPA also provided evidence of tumor not apparent on the unenhanced studies in two cases. Therapy was altered as the assumptions regarding the presence or absence of tumor were changed by contrastenhanced studies.
The findings of the enhanced MR studies were used to guide further therapy in patients with residual tumor. Four patients underwent additional surgery; three displayed a discrete tumor nidus and had further resection (Table 1) were initiated in a 2-year-old boy (Case 5) with a biopsyproven primary leptomeningeal melanoma after the contrast-enhanced study demonstrated diffuse infiltration of the subarachnoid space with tumor (Fig. 3) . This patient's tumor was not appreciated on the unenhanced T~-and T2-weighted studies, and he would not have received these treatments based on these studies. External beam radiation therapy was recommended for the treatment of a residual astrocytoma involving the basal ganglia in Case 13 and a pineocytoma with intraaxial nodules involving the tectum in Case 7 (Fig. 4) . Increased surveillance was initiated for a patient with benign pineal teratoma (Case 9) and for another with craniopharyngioma (Case 8) in whom the enhanced studies displayed an additional tumor nodule, Patients without evidence of residual or recurrent disease are followed annually or biannually with examinations and radiographic studies.
Discussion
The N-methylglucamine salt of Gd-DTPA has been available experimentally for use as a contrast agent in MR imaging since 1983. ~1"~2 The ionic form of Gd is toxic; however, chelation with DTPA neutralizes the toxicity by tightly binding the Gd molecule, preventing the release of free Gd. 2'4 7,~o Extensive laboratory and clinical trials in humans have demonstrated that Gd-DTPA is a safe and effective agent for use in contrastenhanced MR imaging. 3-7'9-j3 Gadolinium-DTPA is distributed primarily in the extracellular space, and enhancement persists for approximately 1 hour following administration. 8'9 It has a half-life of approximately 20 minutes and is excreted unchanged by glomerular filtrationY The short halflife after intravenous administration and the high binding constant (1022 to 1023) of Gd-DTPA account for its stability and favorable kinetic properties. [4] [5] [6] In a similar fashion to iodinated computerized tomography contrast agents, Gd-DTPA must leak into the extracellular space to produce a contrast effect. 3''2 By delineating areas of disruption of the blood-brain bartier, Gd-DTPA has been particularly useful in defining the margins between tumor and edema within the central nervous system (CNS). 1' 3' 4' 7"9"10 The paramagnetic properties of Gd are due to the presence of unpaired electrons. 8"~3 Gadolinium-DTPA does not directly produce an increased signal; it produces local changes in the magnetic environment that alter the signal intensity obtained. Both T~ and T2 relaxation times are shortened. This effect is best visualized on T~-weighted images by a marked increase in signal intensity.
Our study specifically addressed the value of enhanced MR imaging compared to unenhanced MR imaging in the postoperative evaluation of children with primary CNS neoplasms. Gadolinium-DTPA was most useful in the immediate postoperative period for assessing whether the extent of the surgical resection was adequate; however, a number of features displayed by the enhanced MR studies demonstrate the efficacy of this technique in the immediate and long-term surveillance of patients with brain tumors. Edema, ischemia, postoperative and radiation-induced tissue alterations, and tumor appear similar on unenhanced Tz-weighted MR images. These changes are more clearly distinguished from residual or recurrent tumor after the administration of contrast material because of the tumor enhancement. Neoplastic tissue was demonstrated most clearly on the postcontrast Twweighted images. A number of authors 1-4'6'7'm'~2 have recommended the precontrast T2-weighted sequence (which is most sensitive in detecting focal lesions within the brain) as a screening test, and the postcontrast T~-weighted sequence to help characterize the abnormality by the presence or absence of blood-brain barrier breakdown. 
Gd-DTPA-enhanced MR imaging in pediatric brain tumors
In two patients in this series, Gd-DTPA identified tumor not apparent on precontrast studies. We advocate the use of contrast-enhanced MR imaging in patients with a high risk of tumor recurrence, even with normal precontrast MR studies.
Gadolinium-DTPA-enhanced MR imaging has been a safe, effective means of detecting residual or recurrent tumor. Similar to CT contrast material, Gd-DTPA defines areas of disruption of the blood-brain barrier. Compared to CT, this technique has the additional advantages of the superior anatomical resolution, sensitivity, and multiplanar graphic depiction of disease processes visualized with MR imaging. This technique provides an improved method of differentiating edema and postoperative and postradiation changes from residual tumor tissue. Identification and delineation of the tumor core are also improved with enhanced MR imaging. Enhanced MR imaging is of most value when it is applied to the long-term surveillance and the postoperative assessment of patients with CNS neoplasms.
